Recordati: Isturisa® (Osilodrostat) Approved In The U.S.

Author's Avatar
Mar 09, 2020
Article's Main Image

Recordati Announces US NDA Approval of Isturisa® (osilodrostat), the First and Only FDA Approved Cortisol Synthesis Inhibitor for Patients with Cushing's Disease. Company Builds Endocrinology Business Unit in the U.S.

PR Newswire